The award reflects LLS’s growing presence across the Asia-Pacific health and nutrition sector and its commitment to science-led cellular health innovation.
Longevity Life Sciences has received the 品质科技突破领航企业奖 translated as the ‘Quality Technology Breakthrough Pioneer Enterprise Award’, at the 2026 Hi Health Awards in Shanghai.
The award was presented during the 2026 Healthplex Expo / Natural & Nutraceutical Products China exhibition, held at the National Exhibition and Convention Center in Shanghai from 15–17 June 2026. The event is organised by CCCMHPIE, Sinoexpo Informa Markets, Informa Markets and the Trade Development Bureau of China’s Ministry of Commerce.
LLS participated in the Australian Pavilion at Healthplex Shanghai, alongside established Australian complementary medicine businesses. Complementary Medicines Australia subsequently acknowledged LLS among the Australian Pavilion exhibitors representing the quality, innovation and international reputation of Australia’s complementary medicines sector.
The award follows a period of significant developments for LLS, including the establishment of Australia’s regulated pathway for NMN, the commercialisation of CellVive NMN®, the expansion of its research and biotechnology partnerships and the development of a broader cellular health ingredient pipeline.
Asia-Pacific represents an important part of LLS’s international strategy. The region brings together sophisticated health markets, significant biotechnology and manufacturing capabilities, and growing scientific and commercial interest in cellular health and healthy ageing.
For LLS, the Hi Health recognition is an encouraging acknowledgement of the company’s approach: bringing together science, quality, regulation and commercial translation to advance cellular health.
